X0206 3 2018-12-07 0 0001682852 Moderna, Inc. MRNA 0001239757 LANGER ROBERT C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 11462402 D Common Stock 14132 I By: Michael D. Langer Irrevocable Trust u/d/t dated 12/14/95 Common Stock 14132 I By: Samuel A. Langer Irrevocable Trust u/d/t dated 12/14/95 Common Stock 14132 I By: Susan K. Langer Irrevocable Trust u/d/t dated 12/14/95 Series G Preferred Stock Common Stock 4559 D Stock Option (Right to Buy) 10.90 2026-02-23 Common Stock 23853 D Stock Option (Right to Buy) 19.15 2026-08-10 Common Stock 80550 D Stock Option (Right to Buy) 19.15 2026-08-10 Common Stock 24165 D Stock Option (Right to Buy) 12.21 2027-02-23 Common Stock 42201 D Stock Option (Right to Buy) 14.22 2028-02-28 Common Stock 40307 D The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Each share of Series G Preferred Stock is convertible into shares of the Issuer's common stock, $0.0001 par value per share ("Common Stock") based on an applicable conversion ratio of 0.45872. Upon the closing of the Issuer's initial public offering, all shares of Series G Preferred Stock will convert into shares of Common Stock of the Issuer. The Series G Preferred Stock has no expiration date. This option is fully vested and exercisable. This option will become fully vested and exercisable on February 28, 2019. Exhibit 24.1: Power of Attorney /s/ Jeffrey Cerio, as Attorney-in-Fact 2018-12-07